Disease Burden and Healthcare Utilization Among Patients with Chronic Obstructive Pulmonary Disease (COPD) in England

References

• GOLD. Global initiative for Chronic Obstructive Pulmonary Disease (GOLD). 2021 Report; 2021. Available from: https://goldcopd.org/2021-gold-reports/. Accessed February, 2021.
   Google Scholar
• Rayner L, Sherlock J, Creagh-Brown B, Williams J, deLusignan S. The prevalence of COPD in England: an ontological approach to case detection in primary care. Respir Med. 2017;132:217–225. doi:10.1016/j.rmed.2017.10.024
   PubMed Web of Science ®Google Scholar
• British Lung Foundation. Chronic obstructive pulmonary disease (COPD) statistics; 2020. Available from: https://statistics.blf.org.uk/copd. Accessed July, 2020.
   Google Scholar
• Schnell K, Weiss CO, Lee T, et al. The prevalence of clinically-relevant comorbid conditions in patients with physician-diagnosed COPD: a cross-sectional study using data from NHANES 1999-2008. BMC Pulm Med. 2012;12:26. doi:10.1186/1471-2466-12-26
   PubMed Web of Science ®Google Scholar
• Murtagh E, O’Neill C, McAllister D, Kee F, Macmahon J, Heaney LG. A cross-sectional comparison of direct medical care costs among COPD and asthma patients living in the community in Northern Ireland. Treat Respir Med. 2006;5(6):495–501. doi:10.2165/00151829-200605060-00012
   PubMedGoogle Scholar
• Punekar YS, Landis SH, Wurst K, Le H. Characteristics, disease burden and costs of COPD patients in the two years following initiation of long-acting bronchodilators in UK primary care. Respir Res. 2015;16:141. doi:10.1186/s12931-015-0295-2
   PubMed Web of Science ®Google Scholar
• NICE. NICE guideline - Chronic obstructive pulmonary disease in over 16s: diagnosis and management; 2018. Available from: https://www.nice.org.uk/guidance/ng115. Accessed January, 2021.
   Google Scholar
• GOLD. Global initiative for Chronic Obstructive Pulmonary Disease (GOLD). 2017 Report; 2017. Available from: https://goldcopd.org/wp-content/uploads/2017/02/wms-GOLD-2017-FINAL.pdf. Accessed July, 2020.
   Google Scholar
• Asche CV, Leader S, Plauschinat C, et al. Adherence to current guidelines for chronic obstructive pulmonary disease (COPD) among patients treated with combination of long-acting bronchodilators or inhaled corticosteroids. Int J Chron Obstruct Pulmon Dis. 2012;7:201–209. doi:10.2147/COPD.S25805
   PubMed Web of Science ®Google Scholar
• Visentin E, Nieri D, Vagaggini B, Peruzzi E, Paggiaro P. An observation of prescription behaviors and adherence to guidelines in patients with COPD: real world data from October 2012 to September 2014. Curr Med Res Opin. 2016;32(9):1493–1502. doi:10.1080/03007995.2016.1182900
   PubMed Web of Science ®Google Scholar
• Sansbury LB, Bains C, Lipson DA, Ismaila AS, Landis SH. Real-world treatment patterns of multiple-inhaler triple therapy among patients with chronic obstructive pulmonary disease in UK general practice. Int J Chron Obstruct Pulmon Dis. 2021;16:1255–1264. doi:10.2147/COPD.S290773
   PubMed Web of Science ®Google Scholar
• MRC. Medical Research Council dyspnea scale; 1986. Available from: https://mrc.ukri.org/research/facilities-and-resources-for-researchers/mrc-scales/mrc-dyspnoea-scale-mrc-breathlessness-scale/. Accessed January, 2021.
   Google Scholar
• Rothnie KJ, Müllerová H, Thomas SL, et al. Recording of hospitalizations for acute exacerbations of COPD in UK electronic health care records. Clin Epidemiol. 2016;8:771–782. doi:10.2147/CLEP.S117867
   PubMed Web of Science ®Google Scholar
• Bogart M, Wu B, Germain G, et al. Real-world adherence to single-inhaler vs multiple-inhaler triple therapy among patients with COPD in a commercially insured US population. Chest. 2020;158(4):A1773–A1774. doi:10.1016/j.chest.2020.08.1548
   Web of Science ®Google Scholar
• Halpin D, Rothnie K, Banks V, et al. S27 Are patients with COPD more adherent to fluticasone furoate/umeclidinium/vilanterol (FF/UMEC/VI) compared with multiple-inhaler triple therapy in a real-world UK primary care treated population? Thorax. 2021;76(Suppl 2):A20–A21. Available from: https://thorax.bmj.com/content/76/Suppl_2/A20.2. Accessed February 17, 2022.
   Google Scholar
• Rothnie K, Czira A, Compton C, et al. Are patients with COPD more adherent to single-inhaler compared with multiple-inhaler triple therapy in a real-world UK primary care treated population? Eur Respir J. 2021;58:OA2947. doi: 0.1183/13993003.congress-2021.OA2947
   Web of Science ®Google Scholar
• Gloeckl R, Schneeberger T, Jarosch I, Kenn K. Pulmonary rehabilitation and exercise training in chronic obstructive pulmonary disease. Dtsch Arztebl Int. 2018;115:117–123. doi:10.3238/arztebl.2018.0117
   PubMed Web of Science ®Google Scholar
• Dalon F, Devouassoux G, Belhassen M, et al. Impact of therapy persistence on exacerbations and resource use in patients who initiated COPD therapy. Int J Chron Obstruct Pulmon Dis. 2019;14:2905–2915. doi:10.2147/COPD.S222762
   PubMed Web of Science ®Google Scholar
• Chrystyn H, Small M, Milligan G, Higgins V, Gil EG, Estruch J. Impact of patients’ satisfaction with their inhalers on treatment compliance and health status in COPD. Respir Med. 2014;108(2):358–365. doi:10.1016/j.rmed.2013.09.021
   PubMed Web of Science ®Google Scholar
• Ismaila A, Corriveau D, Vaillancourt J, et al. Impact of adherence to treatment with tiotropium and fluticasone propionate/salmeterol in chronic obstructive pulmonary diseases patients. Curr Med Res Opin. 2014;30(7):1427–1436. doi:10.1185/03007995.2014.908828
   PubMed Web of Science ®Google Scholar
• Toy EL, Beaulieu NU, McHale JM, et al. Treatment of COPD: relationships between daily dosing frequency, adherence, resource use, and costs. Respir Med. 2011;105(3):435–441. doi:10.1016/j.rmed.2010.09.006
   PubMed Web of Science ®Google Scholar
• Vestbo J, Anderson JA, Calverley PMA, et al. Adherence to inhaled therapy, mortality and hospital admission in COPD. Thorax. 2009;64(11):939. doi:10.1136/thx.2009.113662
   PubMed Web of Science ®Google Scholar
• Covvey JR, Mullen AB, Ryan M, et al. A comparison of medication adherence/persistence for asthma and chronic obstructive pulmonary disease in the United Kingdom. Int J Clin Pract. 2014;68(10):1200–1208. doi:10.1111/ijcp.12451
   PubMed Web of Science ®Google Scholar
• Mueller S, Wilke T, Bechtel B, Punekar YS, Mitzner K, Virchow JC. Non-persistence and non-adherence to long-acting COPD medication therapy: a retrospective cohort study based on a large German claims dataset. Respir Med. 2017;122:1–11. doi:10.1016/j.rmed.2016.11.008
   PubMed Web of Science ®Google Scholar
• Wurst KE, St Laurent S, Mullerova H, Davis KJ. Characteristics of patients with COPD newly prescribed a long-acting bronchodilator: a retrospective cohort study. Int J Chron Obstruct Pulmon Dis. 2014;9:1021–1031. doi:10.2147/COPD.S58258
   PubMed Web of Science ®Google Scholar
• Bogart M, Stanford RH, Laliberté F, Germain G, Wu JW, Duh MS. Medication adherence and persistence in chronic obstructive pulmonary disease patients receiving triple therapy in a USA commercially insured population. Int J Chron Obstruct Pulmon Dis. 2019;14:343–352. doi:10.2147/COPD.S184653
   PubMed Web of Science ®Google Scholar
• European Medicines Agency. Trelegy Ellipta Summary of product characteristics; 2019. Available from: https://www.ema.europa.eu/en/documents/product-information/trelegy-ellipta-epar-product-information_en.pdf. Accessed July, 2020.
   Google Scholar
• European Medicines Agency. Trimbow - Summary of product characteristics; 2017. Available from: https://www.ema.europa.eu/en/documents/product-information/trimbow-epar-product-information_en.pdf. Accessed July, 2020.
   Google Scholar
• European Medicines Agency. Trixeo aerosphere - Summary of product characteristics; 2020. Available from: https://www.ema.europa.eu/en/documents/product-information/trixeo-aerosphere-epar-product-information_en.pdf. Accessed January, 2021.
   Google Scholar
• Lai CC, Chen CH, Lin CYH, Wang CY, Wang YH. The effects of single inhaler triple therapy vs single inhaler dual therapy or separate triple therapy for the management of chronic obstructive pulmonary disease: a systematic review and meta-analysis of randomized controlled trials. Int J Chron Obstruct Pulmon Dis. 2019;14:1539–1548. doi:10.2147/COPD.S200846
   PubMed Web of Science ®Google Scholar
• Langham S, Lewis J, Pooley N, et al. Single-inhaler triple therapy in patients with chronic obstructive pulmonary disease: a systematic review. Respir Res. 2019;20(1):242. doi:10.1186/s12931-019-1213-9
   PubMed Web of Science ®Google Scholar
• Lipson DA, Barnacle H, Birk R, et al. FULFIL trial: once-daily triple therapy for patients with chronic obstructive pulmonary disease. Am J Respir Crit Care Med. 2017;196(4):438–446. doi:10.1164/rccm.201703-0449OC
   PubMed Web of Science ®Google Scholar
• Lipson DA, Barnhart F, Brealey N, et al. Once-daily single-inhaler triple versus dual therapy in patients with COPD. N Engl J Med. 2018;378(18):1671–1680. doi:10.1056/NEJMoa1713901
   PubMed Web of Science ®Google Scholar
• Lipson DA, Crim C, Criner GJ, et al. Reduction in all-cause mortality with fluticasone furoate/umeclidinium/vilanterol in patients with chronic obstructive pulmonary disease. Am J Respir Crit Care Med. 2020;201(12):1508–1516. doi:10.1164/rccm.201911-2207OC
   PubMed Web of Science ®Google Scholar
• Tabberer M, Lomas DA, Birk R, et al. Once-daily triple therapy in patients with COPD: patient-reported symptoms and quality of life. Adv Ther. 2018;35(1):56–71. doi:10.1007/s12325-017-0650-4
   PubMed Web of Science ®Google Scholar
• Singh D, Papi A, Corradi M, et al. Single inhaler triple therapy versus inhaled corticosteroid plus long-acting β2-agonist therapy for chronic obstructive pulmonary disease (TRILOGY): a double-blind, parallel group, randomised controlled trial. Lancet. 2016;388(10048):963–973. doi:10.1016/S0140-6736(16)31354-X
   PubMed Web of Science ®Google Scholar
• Rabe KF, Watz H. Chronic obstructive pulmonary disease. Lancet. 2017;389(10082):1931–1940. doi:10.1016/S0140-6736(17)31222-9
   PubMed Web of Science ®Google Scholar
• Halpin DMG, Worsley S, Ismaila AS, et al. INTREPID: single- versus multiple-inhaler triple therapy for COPD in usual clinical practice. ERJ Open Res. 2021;7:00950–02020. doi:10.1183/23120541.00950-2020
   PubMedGoogle Scholar
• Yu AP, Guérin A, Ponce de Leon D, et al. Therapy persistence and adherence in patients with chronic obstructive pulmonary disease: multiple versus single long-acting maintenance inhalers. J Med Econ. 2011;14(4):486–496. doi:10.3111/13696998.2011.594123
   PubMedGoogle Scholar
• Romagnoli A, Santoleri F, Costantin A. Adherence and persistence analysis after three years in real-life of inhalation therapies used in the treatment of COPD. Curr Med Res Opin. 2020;36(12):2055–2061. doi:10.1080/03007995.2020.1841617
   PubMed Web of Science ®Google Scholar
• Miravitlles M, Marín A, Huerta A, Carcedo D, Villacampa A, Puig-Junoy J. Estimation of the clinical and economic impact of an improvement in adherence based on the use of once-daily single-inhaler triple therapy in patients with COPD. Int J Chron Obstruct Pulmon Dis. 2020;15:643–1654. doi:10.2147/COPD.S253567
   Web of Science ®Google Scholar
• Herrett E, Gallagher AM, Bhaskaran K, et al. Data resource profile: Clinical Practice Research Datalink (CPRD). Int J Epidemiol. 2015;44(3):827–836. doi:10.1093/ije/dyv098
   PubMed Web of Science ®Google Scholar